ENLIVEN THERAPEUTICS, INC. Conversion of Stock, Amount Issued
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Conversion of Stock, Amount Issued of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:ConversionOfStockAmountIssued1 · last filed 2025-03-13
- ENLIVEN THERAPEUTICS, INC. conversion of stock, amount issued for the quarter ending 2024-12-31 was $0.00.
- ENLIVEN THERAPEUTICS, INC. conversion of stock, amount issued for the quarter ending 2024-09-30 was $0.00.
- ENLIVEN THERAPEUTICS, INC. conversion of stock, amount issued for the quarter ending 2024-06-30 was $0.00.
- ENLIVEN THERAPEUTICS, INC. conversion of stock, amount issued for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. conversion of stock, amount issued for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- ENLIVEN THERAPEUTICS, INC. conversion of stock, amount issued for fiscal 2023 was $149.75M.
- ENLIVEN THERAPEUTICS, INC. conversion of stock, amount issued for fiscal 2022 was $0.00.
| Period end | Conversion of Stock, Amount Issued 3 month | Conversion of Stock, Amount Issued 6 month | Conversion of Stock, Amount Issued 9 month | Conversion of Stock, Amount Issued 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $0.00 derived: sum of 2 quarters · filed 2025-03-13 | $0.00 derived: sum of 3 quarters · filed 2025-03-13 | $0.00 10-K · filed 2025-03-13 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | $0.00 derived: sum of 4 quarters · filed 2025-03-13 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | $0.00 derived: sum of 3 quarters · filed 2025-03-13 | $0.00 derived: sum of 4 quarters · filed 2025-03-13 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-14 | $0.00 derived: sum of 2 quarters · filed 2025-03-13 | $0.00 derived: sum of 3 quarters · filed 2025-03-13 | $0.00 derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $0.00 derived: sum of 2 quarters · filed 2025-03-13 | $0.00 derived: sum of 3 quarters · filed 2025-03-13 | $149.75M 10-K · filed 2025-03-13 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $149.75M 10-Q · filed 2024-11-13 | $149.75M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $149.75M 10-Q · filed 2024-08-13 | $149.75M derived: sum of 3 quarters · filed 2024-08-13 | $149.75M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $149.75M 10-Q · filed 2024-05-14 | $149.75M derived: sum of 2 quarters · filed 2024-05-14 | $149.75M derived: sum of 3 quarters · filed 2024-05-14 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $0.00 10-K · filed 2024-03-14 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |